Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.52 |
| ▸ | JAK2 | O60674 | 6/20 | 0.49 |
| ▸ | JAK1 | P23458 | 6/20 | 0.49 |
| ▸ | TYK2 | P29597 | 6/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL323137 | 0.91 | JAK3 (0.54) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL15988160 | 0.79 | JAK3 (0.55) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL23717357 | 0.75 | JAK3 (0.74) | JAK3JAK2LCK | |
| SCHEMBL323560 | 0.74 | JAK3 (0.61) | JAK3JAK2LCK | |
| SCHEMBL323632 | 0.74 | JAK3 (0.52) | JAK3LCK | |
| SCHEMBL323133 | 0.74 | JAK3 (0.52) | JAK3JAK2JAK1TYK2LCK | |
| SCHEMBL19012077 | 0.73 | JAK3 (0.72) | JAK3LCK | |
| SCHEMBL323566 | 0.73 | JAK3 (0.51) | JAK3JAK2LCK | |
| SCHEMBL324434 | 0.73 | JAK3 (0.67) | JAK3JAK2LCK | |
| SCHEMBL323751 | 0.73 | JAK3 (0.51) | JAK3JAK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | disclosed |